Shares of Morepen Laboratories Ltd surged nearly 10% in Monday’s trade after the company announced a multi-year global mandate worth approximately Rs 825 crore, marking a significant expansion into the high-growth CDMO segment.
In a press release dated February 23, 2026, the company informed exchanges that it has secured a Contract Development and Manufacturing Organization mandate valued at around Rs 825 crore from a leading global pharma major .
The supplies under this mandate are expected to commence within the next four to five months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes . The company described this as one of the most significant single CDMO mandates in its history.
The deal strengthens Morepen’s global manufacturing footprint and reflects its growing capabilities in regulated markets supported by USFDA, WHO-GMP and EU-approved facilities . The company said its integrated development-to-commercial manufacturing capabilities position it to support complex scale-ups and long-duration supply frameworks.
Chairman and Managing Director Sushil Suri stated that the mandate reflects global customer confidence in Morepen’s quality systems, regulatory track record and execution capabilities .
The announcement comes at a time when global pharmaceutical companies are consolidating supplier networks and partnering with compliant and scalable manufacturing platforms, creating new long-term opportunities for established API players like Morepen .
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.